Anzeige
Mehr »
Mittwoch, 22.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41PJJ | ISIN: SE0026598583 | Ticker-Symbol: 7XB0
Frankfurt
22.10.25 | 08:12
1,239 Euro
-1,71 % -0,022
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XBRANE BIOPHARMA AB Chart 1 Jahr
5-Tage-Chart
XBRANE BIOPHARMA AB 5-Tage-Chart

Aktuelle News zur XBRANE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoXFRA NEW INSTRUMENTS AVAILABLE ON 20.10.2025146The following instruments on XETRA do have their first trading 20.10.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.10.2025 Aktien 1 AU0000177172 iTech Minerals Ltd. 2...
► Artikel lesen
SoXbrane Biopharma AB: Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate1.042Xbrane Biopharma AB ("Xbrane"), a leading Swedish biosimilar developer, announce that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company's Biologics...
► Artikel lesen
FrXFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.10.20251.038The following instruments on Boerse Frankfurt do have their last trading day on 17.10.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.10.2025ISIN NameCA54020J1012 LODESTAR...
► Artikel lesen
XBRANE BIOPHARMA Aktie jetzt für 0€ handeln
FrXFRA ISIN CHANGE308Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenSE0007789409 Xbrane Biopharma AB 17.10.2025 SE0026598583 Xbrane Biopharma AB 20.10.2025 Tausch 125:1GB00B02QND93 PayPoint...
► Artikel lesen
FrXbrane secures conditional SEK 60 mln loan ahead of FDA decision4
FrXbrane sichert sich bedingten Kredit über 60 Mio. SEK für den Fall einer verzögerten FDA-Zulassung5
FrXFRA 7XB: AUSSETZUNG/SUSPENSION352DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILXBRANE BIOPHARMA...
► Artikel lesen
FrXFRA CAPITAL ADJUSTMENT INFORMATION - 17.10.2025763Das Instrument TKA DE0007500001 THYSSENKRUPP AG O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 17.10.2025 und ex Kapitalmassnahme am 20.10.2025 The instrument TKA DE0007500001 THYSSENKRUPP AG O.N....
► Artikel lesen
DoXbrane Biopharma AB: Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S79Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has entered into a financing solution with Fenja Capital II A/S (Fenja) providing a loan of SEK 60 million to be triggered in the event of a delay...
► Artikel lesen
DoReverse split and Change of ISIN for Xbrane Biopharma AB125The company will carry out a reverse stock split in a ratio of 1:125. The share will be traded under new ISIN code with effect from Oct 17, 2025. The order book will not change. Short...
► Artikel lesen
15.10.Xbrane Biopharma AB: Record date for reverse share split in Xbrane Biopharma AB561At the Extra General Meeting of Xbrane Biopharma AB ("Xbrane" or the "Company") held on 13 October 2025, it was resolved to carry out a reverse share split in the ratio 1:125, whereby 125 existing shares...
► Artikel lesen
13.10.Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB98Today on 13 October 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting. Amendments of the articles of associationThe...
► Artikel lesen
01.09.Xbrane Biopharma Q2 2025 slides reveal Ximluci market share gains amid financial restructuring4
01.09.Xbrane Q2 2025: Ximluci gewinnt Marktanteile8
26.08.Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2025167Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2025, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2025*• Revenue amounted...
► Artikel lesen
03.07.Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB311Today on 3 July 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting. Resolution regarding approval of the board of...
► Artikel lesen
11.06.Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane2
04.06.Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia362Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane...
► Artikel lesen
23.05.Xbrane Biopharma AB: Xbrane Biopharma AB (publ) updates on US FDA BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS (ranibizumab)458Xbrane re-submitted the BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) to the FDA (US Food and Drug Administration) in December 2024. After...
► Artikel lesen
08.05.Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report January-March 2025339Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report January-March 2025, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1